Why Roivant Sciences Stock is Trading Higher Today
Portfolio Pulse from Vandana Singh
Roivant Sciences Ltd (NASDAQ:ROIV) reported positive results from the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with moderate to severe ulcerative colitis. The data showed sustained efficacy across a broad dose range measured at 56 weeks, with no impact of immunogenicity on clinical efficacy or safety results. ROIV shares are up 13.00% at $10.76.
June 22, 2023 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences reported positive results from the TUSCANY-2 Phase 2b study of RVT-3101, showing sustained efficacy and safety. Shares are up 13.00% at $10.76.
The positive results from the TUSCANY-2 Phase 2b study of RVT-3101 indicate that the drug has potential in treating moderate to severe ulcerative colitis. This news is likely to boost investor confidence in the company's pipeline and future prospects, leading to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100